Bioavailable

New drugs, peptides, and emerging therapies. Evidence-first.

[Bioavailable @bio_available_]

Thanks for the follows folks! Will make it worth your while! Pretty new to twitter but will aim to be more active here going forward!

[Abud Bakri MD @AbudBakri]

Bewildering indeed

And each organ has a different dipeptide signature

[Bioavailable @bio_available_]

BPC-157 Explained : )

[Abud Bakri MD @AbudBakri]

Vilon is a fragment of both TA1 and TB4, and seems to maintain or modulate some of the effects of the parent compounds

In a study of 520 people taking oral vilon after a respiratory illness, the Vilon group had positive effects both on immune markers and subjective symptomatic recovery

Human data pretty large study

Promising compound, but more data on the bioregulators than the other peptides if you know where to look

[Bioavailable @bio_available_]

@DrJesseMorse Let's go!

[Bioavailable @bio_available_]

@droppingginn1 thats awesome! I just love science! Trying to build and (hopefully) grow in private for the next few years then will change branding to incorporate my identity :)

will always try my best to provide evidence-based explainer videos!

[Bioavailable @bio_available_]

We covered a lot this week: BPC-157, retatrutide, MOTS-c, semaglutide, the growth hormone peptides, epitalon, and Semax.

Which mechanism surprised you most?

And what should I break down next week? The best replies usually become the next threads.

[Bioavailable @bio_available_]

Great episode

[Tim Ferriss @tferriss]

NEW podcast episode is up!

Dr. Andrew Huberman — Peptides, Performance, and Protocols

Andrew Huberman, Ph.D., is a neuroscientist and tenured professor in the Departments of Neurobiology and Ophthalmology at Stanford University School of Medicine, where he runs the Huberman Lab.

He is the author of Protocols: An Operating Manual for the Human Body.

Please enjoy! 🙌

cc: @hubermanlab

[Bioavailable @bio_available_]

@DrJesseMorse @stackapp Good predictions ahead of the meeting by Dr. Morse

[Bioavailable @bio_available_]

@droppingginn1 I think their main concerns were lack of evidence but DSIP definitely has promise mechanistically! And yes, I do :)

[Bioavailable @bio_available_]

well said!

[Abud Bakri MD @AbudBakri]

The drug approval process doesn’t meet the current population it seeks the protect. This is what people are missing

The current model of is designed to approve drugs to treat specific conditions

How do you get drugs approved that are.. to improve performance and “wellness”, whatever that means to you.

SS-31 got approved for a rare condition but millions more doses will be used for “mitochondrial health”

Tesamorelin is approved for HIV lipodystrophy but actual usage is in the performance space

These were glitches that get drugs through

We need a process to get safe usage of performance and longevity medicine compounds. Not just this batch of peptides

There will be hundreds more

A regulatory space needs to develop

[Bioavailable @bio_available_]

@drmarlonperalta Agree!

[Bioavailable @bio_available_]

FDA PCAC Meeting Full Results (July 23 & July 24)

Should The Following Peptides Be Allowed to Be Compounded in America? (Majority Vote)

Day 1:
BPC-157 ✅
KPV ✅
TB-500 ✅
MOTS-C ✅

Day 2:
DSIP (Emideltide) ❌
Epitalon ✅
Semax ✅

[Bioavailable @bio_available_]

YES

[Jesse Morse, M.D. @DrJesseMorse]

🚨 The vote for Epithalon is in!

Yes (7), No (4), Abstained (1)

Overall conclusion = YES ✅

This vote will be considered by the full committee, FDA, and RFJ Jr.

[Bioavailable @bio_available_]

@PepMariner Thanks for watching!

[Bioavailable @bio_available_]

Epitalon Explained : )

[Bioavailable @bio_available_]

@DrJesseMorse Amazing! Looking forward to it!

[Bioavailable @bio_available_]

Emildeltide Free Base (DSIP) is a NO

6 Yes, 7 No